Insurers balk at covering GYN treatment by OhioHealth
OhioHealth recently spent $3.5 million on equipment for a less-invasive treatment of benign but sometimes problematic tumors that grow on the uterus. And the health system has spent additional money to advertise the outpatient uterine-fibroid procedure, which was approved by the U.S. Food and Drug Administration eight years ago. OhioHealth officials said they anticipated some initial push-back from insurers to paying for the procedure, which OhioHealth had expected to perform 80 to 100 times a year by 2014. But the reluctance, they said, has been far greater than expected from health insurers such as Anthem, Aetna and Medical Mutual of Ohio.
- Senators Hear How Two-Midnight Rule Harms Patients, Hospitals
- 3 Management Lessons from a Supermarket Debacle
- Handshaking Spreads Germs. Get Over It.
- Healthcare Costs Start With What We Eat
- Hospitals Likely to Outsource ICD-10 at Launch
- IOM Identifies GME Problems, Calls for Finance Changes
- CMS Confirms ICD-10 Deadline
- Anatomy of 3 Health System Rebranding Efforts
- Premium Subsidy Fight Creating Uncertainty for Hospitals, Health Plans
- 2015 HIX Premium Hikes May Top 7%